http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Japan’s High-Technology Trade with China and Its Export Control
Tomoo Marukawa 동아시아연구원 2013 Journal of East Asian Studies Vol.13 No.3
While Japanese business interests support the export of high-technology items and the transfer of technology from Japan to China, these economically motivated actions may have direct and indirect impacts on Japan’s national security. First, the transfer of dual-use technology to China may directly help China’s military buildup. Second, high-tech exports and technology transfers may have an indirect effect by eroding Japan’s technological advantages vis-à-vis China. In this article I place these concerns into a historical context and analyze the current challenges to Japan’s export control policies. I offer an overview of the Japan-China trade relationship, with a special focus on high-tech trade. I then discuss changes in Japan’s export controls regarding China, based on heightened security concerns. Evidence indicates that the Japanese government is ill equipped to deal with “technology leakage,” which is accelerating the erosion of Japan’s technological supremacy and is not covered by its current export control regime.
Tomoo Nakagawa,Taku Kobayashi,Kiyohiro Nishikawa,Fumika Yamada,Satoshi Asai,Yukinori Sameshima,Yasuo Suzuki,Mamoru Watanabe,Toshifumi Hibi 대한장연구학회 2019 Intestinal Research Vol.17 No.4
Background/Aims: An interim analysis of post-marketing surveillance of CT-P13, an infliximab biosimilar, was performed to evaluate its safety and efficacy in Japanese patients with inflammatory bowel disease. Methods: Patients were prospectively enrolled between November 2014 and March 2017, after the launch of CT-P13 in Japan, and case report forms of patients followed for at least 4 months were analyzed as of July 2018. Results: Of 523 patients in the analysis set, 372 remained on CT-P13 therapy, while 54 (20.2%) of 267 patients with Crohn’s disease, and 97 (37.9%) of 256 patients with ulcerative colitis were withdrawn during follow-up. A total of 144 adverse drug reactions (ADRs) were reported in 106 patients (20.3%). Infusion reaction was the most frequent ADR observed in 49 patients (9.4%). Efficacy parameters decreased immediately after the start of treatment in naïve patients to anti-tumor necrosis factor-α antibody. In the patients switched from originator infliximab for nonmedical reasons, the decreased parameters due to proceeded treatment with the originator were maintained in low ranges, and the treatment continuation rate was high with low ADR incidence. In contrast, in patients switched for medical reasons such as adverse event or loss of response, the incidence of ADRs was high. However, the efficacy parameters were improved, and the treatment continuation rate was not significantly different from that of the naïve patient group. Conclusions: In this interim analysis, CT-P13 was comparable to the originator infliximab with respect to ADRs and efficacy, and is therefore considered to be a cost-efficient interchangeable biosimilar for Japanese patients with inflammatory bowel disease.